306 results on '"Larché M"'
Search Results
2. Collection of antirheumatic medication data from both patients and rheumatologists shows strong agreement in a real-world clinical cohort: the Ontario Best Practices Research Initiative—a rheumatoid arthritis cohort
3. Value of 111In-Pentetreotide scintigraphy and 18F-FDG PET for clinical prognosis of patients with neuroendocrine neoplasms
4. Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin‐induced thrombocytopenia
5. Organic solvent exposure and systemic sclerosis: A retrospective cohort study based on the Canadian Scleroderma Research Group registry
6. Elevated CD27-IgD- B cells in Post-Acute COVID-19 Sequalae Patients with Rheumatological Symptoms
7. The Impact of Pain and Itch on Functioning and Health-Related Quality of Life in Systemic Sclerosis: An Exploratory Study
8. The association of sociodemographic and objectively-assessed disease variables with fatigue in systemic sclerosis: an analysis of 785 Canadian Scleroderma Research Group Registry patients
9. POS0111 MORE METICULOUSLY FOLLOWING TREAT-TO-TARGET IN RA DOES NOT LEAD TO LESS RADIOGRAPHIC PROGRESSION: A LONGITUDINAL ANALYSIS IN BIODAM
10. Association Between Immunosuppressive Therapy and Incident Risk of Interstitial Lung Disease in Systemic Sclerosis
11. One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence
12. Treatment with anti-cytokine monoclonal antibodies can potentiate the target cytokine rather than neutralize its activity
13. T regulatory cell phenotypes in peripheral blood and bronchoalveolar lavage from non-asthmatic and asthmatic subjects
14. The Canadian Healthy Infant Longitudinal Development (CHILD) Study: examining developmental origins of allergy and asthma
15. Damage Trajectories in Systemic Sclerosis Using Group‐BasedTrajectory Modeling
16. Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects
17. Comprehensive metabolomics identifies the alarmin uric acid as a critical signal for the induction of peanut allergy
18. T cell-mediated induction of thymic stromal lymphopoietin in differentiated human primary bronchial epithelial cells
19. OX40L blockade and allergen-induced airway responses in subjects with mild asthma
20. Cytokine responses of peripheral blood mononuclear cells to allergen do not identify asthma or asthma phenotypes
21. Indirect Recognition of T-Cell Epitopes Derived from the α3 and Transmembrane Domain of HLA-A2
22. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy
23. Immunotherapy with peptides
24. Development and Preliminary Clinical Evaluation of a Peptide Immunotherapy Vaccine for Cat Allergy: 843
25. Induction of Thymic Stromal Lymphopoietin (TSLP) in Airway Epithelium by Recombinant Allergens: 474
26. Mammalian target of rapamycin is activated in the kidneys of patients with scleroderma renal crisis
27. Of cats and men: immunodominance and the role of HLA-DP/DQ
28. Airway expression of calcitonin gene-related peptide in T-cell peptide-induced late asthmatic reactions in atopics
29. Peptide immunotherapy for allergic diseases
30. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy
31. Peptide therapy in allergic disease: IS42
32. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects
33. Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-Ω+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects
34. Acute cat allergen challenge recruits T1/ST2+ but not Tim 3+ CD4+ cells to lungs of DR1 transgenic mice: 6.13
35. Cat allergen peptide immunotherapy reduces CD4+ T cell responses to cat allergen but does not alter suppression by CD4+ CD25+ T cells: a double-blind placebo-controlled study
36. Therapeutic tolerance in a HLA DR1-transgenic murine model of cat allergen sensitivity
37. Anti-T-cell strategies in the treatment of allergic disease
38. Changes in interferon-γ production following specific allergen immunotherapy: biology vs methodology
39. BLOOD EOSINOPHILS FROM ATOPIC DONORS EXPRESS mRNA FOR THE α,β AND γ SUBUNITS OF THE HIGH AFFINITY IgE RECEPTOR (FcϵRI) AND INTRACELLULAR, BUT NO CELL SURFACE, α SUBUNIT PROTEIN
40. CYTOKINE RESPONSES IN ATOPIC ASTHMATICS TO DISTINCT REGIONS OF A SINGLE ALLERGEN: COMPARISON WITH ATOPIC NON-ASTHMATIC AND NON-ATOPIC CONTROLS
41. ATTENUATION OF BRONCHIAL AND CUTANEOUS ALLERGIC LATE PHASE RESPONSES BY ALLERGEN-DERIVED PEPTIDES
42. Allergen isoforms for immunotherapy: diversity, degeneracy and promiscuity
43. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial
44. T-cell responses to house dust mites: bad news for immunotherapy?
45. Enhanced In Vivo Immunogenicity Induced by an Antibody to the IL-4 Receptor-Associated gp200-MR6 Molecule
46. FcεRI expression on monocytes in atopic disease: cause or effect?
47. Bicaudal D2 is a novel autoantibody target in systemic sclerosis that shares a key epitope with CENP-A but has a distinct clinical phenotype
48. OP0192 Adding ultrasound to the treat-to-target strategy shows no benefit in achievement of remission: results from the biodam cohort
49. Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future - an EAACI Position Paper
50. Novel approaches and perspectives in allergen immunotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.